Psyence Biomedical Ltd
PBMWW0.025USD
0.000
Market hours （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Psyence Biomedical Ltd Company
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Company Info
Ticker SymbolPBMWW
Company namePsyence Biomedical Ltd
IPO dateDec 10, 2021
CEODr. Neil Maresky
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address121 Richmond Street West Penthouse
CityTORONTO
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeM5H 2K1
Phone17744604171
Website
Ticker SymbolPBMWW
IPO dateDec 10, 2021
CEODr. Neil Maresky
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 9
Updated: Wed, Jul 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
54
5.80M
0.00%
-4.43M
2025Q1
56
5.75M
0.00%
-4.55M
2024Q4
58
4.63M
0.00%
-5.55M
2024Q3
65
6.46M
0.00%
-4.73M
2024Q2
67
6.76M
0.00%
-3.47M
2024Q1
67
6.93M
0.00%
-3.84M
2023Q4
66
8.24M
0.00%
-2.37M
2023Q3
64
8.66M
0.00%
-1.45M
2023Q2
63
8.16M
0.00%
-2.52M
2023Q1
62
8.81M
0.00%
-1.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Harraden Circle Investments, LLC
1.15M
0%
--
--
Mar 31, 2025
Polar Asset Management Partners Inc.
733.00K
0%
--
--
Mar 31, 2025
MMCAP Asset Management
600.00K
0%
--
--
Mar 31, 2025
Calamos Advisors LLC
500.00K
0%
--
--
Mar 31, 2025
Cantor Fitzgerald, L.P
468.50K
0%
--
--
Mar 31, 2025
Saba Capital Management, L.P.
297.85K
0%
--
--
Mar 31, 2025
Aristeia Capital, L.L.C.
247.86K
0%
-25.00K
-9.16%
Mar 31, 2025
Goldman Sachs & Company, Inc.
200.12K
0%
--
--
Mar 31, 2025
LMR Partners LLP
200.00K
0%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
